Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s ...

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Small cell lung cancer (SCLC), one of the deadliest types of lung cancer, is an aggressive tumor that metastasizes early compared to other cancers and can quickly develop resistance to chemotherapy — ...

Researchers have now demonstrated for the first time that MNPs can trigger malignant changes in lung cells that are ...

China's domestic biotech industry is entering a new phase of international influence, as homegrown innovative drugs ...

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

A large VA database study showed that surgery improves long-term survival over radiation in veterans with early-stage non-small cell lung cancer.

The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health insurance.

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination ...

Revolution Medicines, Inc. (NASDAQ: RVMD) is one of the best oversold NASDAQ stocks to buy now. On July 15, Goldman Sachs ...